Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar
This article was originally published in The Pink Sheet Daily
Executive Summary
Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.